Gapping up
In reaction to strong earnings/guidance: HAS +5%, MS +2.5%, PEP +0.8%, JBHT +0.5%, .
M&A news: MDVN +3.4% (AstraZeneca (AZN) may bid for MDVN, according to Times UK, also presents Phase I Talazoparib data), .
Select Brazil related names showing strength after lower house calls for impeachment: ITUB +6.1%, CIG +5.9%, BBD+2.3%, VALE +1.9%, VIV +1.3%, PBR +0.6%, .
Other news: IMMU +6.3% (its anti-HLA-DR IgG4 antibody, was superior to anti-CD20 therapy using rituximab), RPRX +3.5% (cont strength), CGEN +2.9% (achieves a first preclinical milestone for CGEN-15022), ONCS +2.3% (names Robert Pierce Chairman of the Scientific Advisory Board & Chief Scientific Strategist), LEI +2% (amends existing convertible note & increases conversion price to $3.25/share from $1.50/share), CCL +1.2% (still checking), JKS +0.8% (announces that it will supply 49 MW of solar modules to China Resources Power Investment Co for three solar PV plants)
Analyst comments: CNHI +3.7% (upgraded to Buy from Neutral at BofA/Merril), JOY +1.8% (upgraded to Neutral from Underperform at BofA/Merrill)
In reaction to strong earnings/guidance: HAS +5%, MS +2.5%, PEP +0.8%, JBHT +0.5%, .
M&A news: MDVN +3.4% (AstraZeneca (AZN) may bid for MDVN, according to Times UK, also presents Phase I Talazoparib data), .
Select Brazil related names showing strength after lower house calls for impeachment: ITUB +6.1%, CIG +5.9%, BBD+2.3%, VALE +1.9%, VIV +1.3%, PBR +0.6%, .
Other news: IMMU +6.3% (its anti-HLA-DR IgG4 antibody, was superior to anti-CD20 therapy using rituximab), RPRX +3.5% (cont strength), CGEN +2.9% (achieves a first preclinical milestone for CGEN-15022), ONCS +2.3% (names Robert Pierce Chairman of the Scientific Advisory Board & Chief Scientific Strategist), LEI +2% (amends existing convertible note & increases conversion price to $3.25/share from $1.50/share), CCL +1.2% (still checking), JKS +0.8% (announces that it will supply 49 MW of solar modules to China Resources Power Investment Co for three solar PV plants)
Analyst comments: CNHI +3.7% (upgraded to Buy from Neutral at BofA/Merril), JOY +1.8% (upgraded to Neutral from Underperform at BofA/Merrill)